Redmile Group’s Cabaletta Bio CABA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-442,826
Closed -$2.09M 63
2024
Q3
$2.09M Hold
442,826
0.12% 57
2024
Q2
$3.31M Hold
442,826
0.2% 53
2024
Q1
$7.55M Sell
442,826
-931,363
-68% -$20M 0.28% 63
2023
Q4
$31.2M Sell
1,374,189
-400,063
-23% -$6.73M 1.12% 28
2023
Q3
$27M Buy
1,774,252
+403,953
+29% +$5.52M 1.28% 25
2023
Q2
$17.7M Buy
1,370,299
+1,096,047
+400% +$11.9M 0.68% 41
2023
Q1
$2.27M Sell
274,252
-190,000
-41% -$1.78M 0.1% 65
2022
Q4
$4.29M Sell
464,252
-232,125
-33% -$845K 0.18% 53
2022
Q3
$453K Hold
696,377
0.02% 69
2022
Q2
$738K Hold
696,377
0.03% 69
2022
Q1
$1.41M Hold
696,377
0.04% 68
2021
Q4
$2.64M Hold
696,377
0.06% 69
2021
Q3
$8.47M Sell
696,377
-1
-0% -$9 0.15% 66
2021
Q2
$5.99M Hold
696,378
0.09% 78
2021
Q1
$7.73M Sell
696,378
-681,941
-49% -$8.33M 0.11% 76
2020
Q4
$17.2M Sell
1,378,319
-8,265
-0.6% -$107K 0.21% 65
2020
Q3
$15M Sell
1,386,584
-39,312
-3% -$452K 0.28% 60
2020
Q2
$15.9M Hold
1,425,896
0.29% 61
2020
Q1
$10.4M Sell
1,425,896
-5,800
-0.4% -$79.5K 0.29% 53
2019
Q4
$20M Buy
+1,431,696
New +$17M 0.48% 50

Other funds holding CABA

Redmile Group's CABA Position: Q4 2024 in Review

Redmile Group sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 442,826 shares — an estimated $2.09M sold.

Redmile Group first reported a position in CABA in Q4 2019 and held it in 20 quarters. The position peaked at $31.2M in Q4 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • Redmile Group reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • Redmile Group sold 442,826 Cabaletta Bio shares in Q4 2024, an estimated $2.09M.
  • Redmile Group first reported a position in Cabaletta Bio in Q4 2019 and held it in 20 quarters.
  • Redmile Group's Cabaletta Bio position peaked at $31.2M in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on Redmile Group's 13F filing for Q4 2024, filed 14 Feb 2025.